UNSPSC 51173207: Bisacodyl/docusate/senna concentrate/senna extract/sucrose

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.

UNSPSC 51173207 Bisacodyl/docusate/senna concentrate/senna extract/sucrose (Commodity) identifies a narrow class of over-the-counter laxative and stool-softener products. The recent state and local procurement activity under this code, however, shows little direct alignment with the commodity itself. Of the three opportunities posted, two concern pharmaceutical procurement at scale—generic drugs and OTC products broadly, and direct-to-manufacturer prescription programs—while the third addresses offender drug testing services unrelated to laxative ingredients. The code's abstract scope and the actual work being solicited diverge substantially, suggesting either misclassification at posting or that this commodity code captures only incidental demand within larger pharmaceutical-procurement initiatives.

The issuing bodies include a Texas county criminal-justice department (Collin County Community Supervision and Corrections), the Texas Health and Human Services Commission, and a multistate cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). Geographic activity centers on Texas and the Upper Midwest (Minnesota and Oregon participate in MMCAP). The most recent opportunity, Collin County's RFP 2026-327 for offender specimen collection and drug testing services (due July 23, 2026, estimated value $600,000), addresses testing logistics and lab certification rather than laxative procurement. MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, contract term two years effective July 1, 2026) shows broader pharmaceutical supply but does not isolate laxative products in its posted summary. The Texas HHS Commission's RFI HHS0017013 on direct-to-manufacturer prescriptions (posted March 27, 2026, response deadline April 3, 2026) is an exploratory market-intelligence instrument preceding formal solicitation. This code shows minimal recent activity specifically targeting the named laxative formulations.